Potent antitumor and antineoplastic efficacy of baicalein on benzo(a)pyrene-induced experimental pulmonary tumorigenesis

Chandrashekar Naveenkumar, Selvamani Asokkumar, Subramanian Raghunandhakumar, Sundaram Jagan, Pandi Anandakumar, Titto A. Augustine, Sattu Kamaraj, Thiruvengadam Devaki

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Current study aims to evaluate the efficacy of baicalein (BE), a naturally occurring bioactive flavanoid (5,6,7-trihydroxy-flavone), at a dose of 12mg/kg body wt in Swiss albino mice exposed to tobacco-specific carcinogen benzo(a)pyrene [B(a)P] (50mg/kg body wt) for its ability to mitigate pulmonary adenoma formation and growth. Under coarse observation, B(a)P-administered mice, after 16weeks, developed macroscopically detectable tumors, whereas oral treatment with BE to the lung cancer-induced mice significantly reduced tumor incidence in 16-week pre- and posttreated groups. A detailed histopathological examination of lung was conducted to determine the degree of cancer progression. Incidence of anaplasia, hyperplasia, dysplasia, severe dysplasia, and adenocarcinoma were evident in carcinogen-administrated group in 6, 10, 12, 14, and 16th weeks, respectively, whereas these anomalies were effectively reduced after pre- and posttreatment with BE. In the pretreatment group, BE significantly arrested tumor multiplicity by approximately 65% and tumor load by approximately 88%, while in the posttreatment, the compound significantly reduced the tumor multiplicity by approximately 48% and tumor load by approximately 61%. Further analysis of serum tumor markers like carcinoembryonic antigen, CK 19 fragments (CYFRA 21-1), and tissue marker enzymes like aryl hydrocarbon hydroxylase, adenosine deaminase, γ-glutamyl transpeptidase, 5′-nucleotidase, and lactate dehydrogenase in serum and lung homogenate was carried out to substantiate the anticarcinogenic effect of BE. The overall data from our experiments suggested that BE significantly inhibited pulmonary adenoma formation and growth, thus revealing its potent antitumorigenic effect.

Original languageEnglish (US)
Pages (from-to)259-270
Number of pages12
JournalFundamental and Clinical Pharmacology
Volume26
Issue number2
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Benzo(a)pyrene
Antineoplastic Agents
Carcinogenesis
Lung
flavone
Neoplasms
Tumor Burden
Carcinogens
Adenoma
Anaplasia
Anticarcinogenic Agents
Aryl Hydrocarbon Hydroxylases
5'-Nucleotidase
Adenosine Deaminase
gamma-Glutamyltransferase
Carcinoembryonic Antigen
Incidence
Tumor Biomarkers
Growth
L-Lactate Dehydrogenase

Keywords

  • Baicalein
  • Benzo(a)pyrene
  • Chemoprevention
  • Neoplastic lesions
  • Pulmonary tumorigenesis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Potent antitumor and antineoplastic efficacy of baicalein on benzo(a)pyrene-induced experimental pulmonary tumorigenesis. / Naveenkumar, Chandrashekar; Asokkumar, Selvamani; Raghunandhakumar, Subramanian; Jagan, Sundaram; Anandakumar, Pandi; Augustine, Titto A.; Kamaraj, Sattu; Devaki, Thiruvengadam.

In: Fundamental and Clinical Pharmacology, Vol. 26, No. 2, 04.2012, p. 259-270.

Research output: Contribution to journalArticle

Naveenkumar, Chandrashekar ; Asokkumar, Selvamani ; Raghunandhakumar, Subramanian ; Jagan, Sundaram ; Anandakumar, Pandi ; Augustine, Titto A. ; Kamaraj, Sattu ; Devaki, Thiruvengadam. / Potent antitumor and antineoplastic efficacy of baicalein on benzo(a)pyrene-induced experimental pulmonary tumorigenesis. In: Fundamental and Clinical Pharmacology. 2012 ; Vol. 26, No. 2. pp. 259-270.
@article{3d156a7f43b547eea7c0e9d897620f17,
title = "Potent antitumor and antineoplastic efficacy of baicalein on benzo(a)pyrene-induced experimental pulmonary tumorigenesis",
abstract = "Current study aims to evaluate the efficacy of baicalein (BE), a naturally occurring bioactive flavanoid (5,6,7-trihydroxy-flavone), at a dose of 12mg/kg body wt in Swiss albino mice exposed to tobacco-specific carcinogen benzo(a)pyrene [B(a)P] (50mg/kg body wt) for its ability to mitigate pulmonary adenoma formation and growth. Under coarse observation, B(a)P-administered mice, after 16weeks, developed macroscopically detectable tumors, whereas oral treatment with BE to the lung cancer-induced mice significantly reduced tumor incidence in 16-week pre- and posttreated groups. A detailed histopathological examination of lung was conducted to determine the degree of cancer progression. Incidence of anaplasia, hyperplasia, dysplasia, severe dysplasia, and adenocarcinoma were evident in carcinogen-administrated group in 6, 10, 12, 14, and 16th weeks, respectively, whereas these anomalies were effectively reduced after pre- and posttreatment with BE. In the pretreatment group, BE significantly arrested tumor multiplicity by approximately 65{\%} and tumor load by approximately 88{\%}, while in the posttreatment, the compound significantly reduced the tumor multiplicity by approximately 48{\%} and tumor load by approximately 61{\%}. Further analysis of serum tumor markers like carcinoembryonic antigen, CK 19 fragments (CYFRA 21-1), and tissue marker enzymes like aryl hydrocarbon hydroxylase, adenosine deaminase, γ-glutamyl transpeptidase, 5′-nucleotidase, and lactate dehydrogenase in serum and lung homogenate was carried out to substantiate the anticarcinogenic effect of BE. The overall data from our experiments suggested that BE significantly inhibited pulmonary adenoma formation and growth, thus revealing its potent antitumorigenic effect.",
keywords = "Baicalein, Benzo(a)pyrene, Chemoprevention, Neoplastic lesions, Pulmonary tumorigenesis",
author = "Chandrashekar Naveenkumar and Selvamani Asokkumar and Subramanian Raghunandhakumar and Sundaram Jagan and Pandi Anandakumar and Augustine, {Titto A.} and Sattu Kamaraj and Thiruvengadam Devaki",
year = "2012",
month = "4",
doi = "10.1111/j.1472-8206.2010.00910.x",
language = "English (US)",
volume = "26",
pages = "259--270",
journal = "Fundamental and Clinical Pharmacology",
issn = "0767-3981",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Potent antitumor and antineoplastic efficacy of baicalein on benzo(a)pyrene-induced experimental pulmonary tumorigenesis

AU - Naveenkumar, Chandrashekar

AU - Asokkumar, Selvamani

AU - Raghunandhakumar, Subramanian

AU - Jagan, Sundaram

AU - Anandakumar, Pandi

AU - Augustine, Titto A.

AU - Kamaraj, Sattu

AU - Devaki, Thiruvengadam

PY - 2012/4

Y1 - 2012/4

N2 - Current study aims to evaluate the efficacy of baicalein (BE), a naturally occurring bioactive flavanoid (5,6,7-trihydroxy-flavone), at a dose of 12mg/kg body wt in Swiss albino mice exposed to tobacco-specific carcinogen benzo(a)pyrene [B(a)P] (50mg/kg body wt) for its ability to mitigate pulmonary adenoma formation and growth. Under coarse observation, B(a)P-administered mice, after 16weeks, developed macroscopically detectable tumors, whereas oral treatment with BE to the lung cancer-induced mice significantly reduced tumor incidence in 16-week pre- and posttreated groups. A detailed histopathological examination of lung was conducted to determine the degree of cancer progression. Incidence of anaplasia, hyperplasia, dysplasia, severe dysplasia, and adenocarcinoma were evident in carcinogen-administrated group in 6, 10, 12, 14, and 16th weeks, respectively, whereas these anomalies were effectively reduced after pre- and posttreatment with BE. In the pretreatment group, BE significantly arrested tumor multiplicity by approximately 65% and tumor load by approximately 88%, while in the posttreatment, the compound significantly reduced the tumor multiplicity by approximately 48% and tumor load by approximately 61%. Further analysis of serum tumor markers like carcinoembryonic antigen, CK 19 fragments (CYFRA 21-1), and tissue marker enzymes like aryl hydrocarbon hydroxylase, adenosine deaminase, γ-glutamyl transpeptidase, 5′-nucleotidase, and lactate dehydrogenase in serum and lung homogenate was carried out to substantiate the anticarcinogenic effect of BE. The overall data from our experiments suggested that BE significantly inhibited pulmonary adenoma formation and growth, thus revealing its potent antitumorigenic effect.

AB - Current study aims to evaluate the efficacy of baicalein (BE), a naturally occurring bioactive flavanoid (5,6,7-trihydroxy-flavone), at a dose of 12mg/kg body wt in Swiss albino mice exposed to tobacco-specific carcinogen benzo(a)pyrene [B(a)P] (50mg/kg body wt) for its ability to mitigate pulmonary adenoma formation and growth. Under coarse observation, B(a)P-administered mice, after 16weeks, developed macroscopically detectable tumors, whereas oral treatment with BE to the lung cancer-induced mice significantly reduced tumor incidence in 16-week pre- and posttreated groups. A detailed histopathological examination of lung was conducted to determine the degree of cancer progression. Incidence of anaplasia, hyperplasia, dysplasia, severe dysplasia, and adenocarcinoma were evident in carcinogen-administrated group in 6, 10, 12, 14, and 16th weeks, respectively, whereas these anomalies were effectively reduced after pre- and posttreatment with BE. In the pretreatment group, BE significantly arrested tumor multiplicity by approximately 65% and tumor load by approximately 88%, while in the posttreatment, the compound significantly reduced the tumor multiplicity by approximately 48% and tumor load by approximately 61%. Further analysis of serum tumor markers like carcinoembryonic antigen, CK 19 fragments (CYFRA 21-1), and tissue marker enzymes like aryl hydrocarbon hydroxylase, adenosine deaminase, γ-glutamyl transpeptidase, 5′-nucleotidase, and lactate dehydrogenase in serum and lung homogenate was carried out to substantiate the anticarcinogenic effect of BE. The overall data from our experiments suggested that BE significantly inhibited pulmonary adenoma formation and growth, thus revealing its potent antitumorigenic effect.

KW - Baicalein

KW - Benzo(a)pyrene

KW - Chemoprevention

KW - Neoplastic lesions

KW - Pulmonary tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=84858066600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858066600&partnerID=8YFLogxK

U2 - 10.1111/j.1472-8206.2010.00910.x

DO - 10.1111/j.1472-8206.2010.00910.x

M3 - Article

VL - 26

SP - 259

EP - 270

JO - Fundamental and Clinical Pharmacology

JF - Fundamental and Clinical Pharmacology

SN - 0767-3981

IS - 2

ER -